Abnormally expressed long noncoding RNA B3GALT5‐AS1 may serve as a biomarker for the diagnostic and prognostic of gastric cancer

Abstract Early diagnosis of gastric cancer (GC) is an effective method to improve prognosis. Increasing number of long noncoding RNAs (lncRNAs) have been reported as biomarkers for several cancers. We aim to detect the level of lncRNA B3GALT5‐AS1 and its association with clinical parameters and to further explore its application value in GC. We measured serum B3GALT5‐AS1 expression in 107 patients with GC, 40 polyp patients, and 87 normal controls to explore the significance of serum B3GALT5‐AS1 in GC using the quantitative real‐time polymerase chain reaction method. The result demonstrated that B3GALT5‐AS1 level was markedly richer in GC patients than that in normal people ( P < .001). B3GALT5‐AS1 may be served as a diagnostic marker for distinguishing GC patients from healthy people, and the proportion under the receiver operating characteristics curve is 0.816 (95% confidence interval, 0.758‐0.874; P = .03). Further exploration validated that high serum B3GALT5‐AS1 level was related to TNM stage ( P = .024), and lymph node metastasis ( P = .023). Our study suggested that serum B3GALT5‐AS1 may be employed as an ideal biomarker for early screening of GC.